Asthma Rescue Drug & Delivery Device
In Phase II Clinical Trials
SolAeroMed is a company dedicated to the development of novel therapeutic strategies to treat obstructive lung diseases. Our lead asthma drug, S-1226, is in Phase II clinical trials designed to demonstrate Proof of Concept.
For more information, please see our Business Presentation.
SolAeroMed Annual General Meeting
Join us at our AGM.
Date: June 30, 2015
Time: 4pm – 6pm
Location: SolAeroMed offices
(3535 Research Road NW, Calgary)